MedTrace Logo

Efficacy and Safety Evaluation of U01(ssCART-19) in B-Cell Lymphoma

NCT06987916 · Status: RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2025-06-05

No results posted yet for this study

Summary

This is an open-label phase1 study to assess the safety and efficacy of U01(ssCART-19) cell therapy in the treatment of patients with refractory or recurrent B-cell lymphoma .

Conditions

  • B Cell Lymphoma

Interventions

BIOLOGICAL

ssCART-19

autologous T cells transduced with a lentiviral vector containing anti-CD19 CAR and small hairpin RNA to silence the IL-6 gene

Sponsors & Collaborators

  • Shanghai Tongji Hospital, Tongji University School of Medicine

    lead OTHER

Principal Investigators

  • Wenjun Zhang, Doctor · Tongji hospital of tongji university (Shanghai tongji hospital)

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
2 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-04-22
Primary Completion
2028-04-22
Completion
2030-04-22

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06987916 on ClinicalTrials.gov